- Home
- VERU
VERU
Veru Inc.
as 03-28-2025 4:00pm EST
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | N/A | IPO Year: | 1990 |
| Target Price: | $4.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.45 - $1.92 | Next Earning Date: | 05-07-2025 |
| Revenue: | $16,886,419 | Revenue Growth: | 22.46% |
| Revenue Growth (this year): | -79.58% | Revenue Growth (next year): | 30.16% |
Stock Insider Trading Activity of Veru Inc. (VERU)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rankowitz Michael L | VERU | Director | Feb 18 '25 | Buy | $0.57 | 150,000 | $84,350.79 | 195,279 |
Latest Veru Inc. News
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
Here's Why Veru (VERU) Looks Ripe for Bottom Fishing
Zacks
25 days ago
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround
Simply Wall St.
a month ago
3 US Penny Stocks With Market Caps Under $300M To Consider
GuruFocus.com
a month ago
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...
GlobeNewswire
2 months ago
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
GuruFocus.com
2 months ago
Veru Inc (VERU) Q1 2025 Earnings Report Preview: What To Expect
GlobeNewswire
2 months ago
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
GlobeNewswire
2 months ago
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compare VERU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.